title: Prescription-filling rates for key medications in Veterans Affairs patients after coronary artery bypass grafting.
abstract: OBJECTIVE
  The six-month prescription-filling rates for key secondary-prevention drugs in Department of Veterans Affairs (VA) patients who had undergone coronary artery bypass grafting (CABG) were studied.
  
  
  METHODS
  Patient records for elective CABG from April 2000 through March 2002 (divided into four six-month periods) were analyzed. The study population included 8925 CABG-only patients surviving to hospital discharge. For each six-month period and in aggregate, the primary study endpoint was the six-month prescription-filling rate.
  
  
  RESULTS
  Across the four six-month periods, prescription-filling rates increased for all categories of medications studied. There were modest progressive increases for lipid-lowering agents, statins, -blockers, angiotensin-converting-enzyme Inhibitors, and angiotensin-receptor blockers. The antithrombotic-filling rate averaged 88.5%. Filling rates for aspirin were much higher than for aspirin alternatives.
  
  
  CONCLUSIONS
  Prescription-filling rates for post-CABG medications in VA facilities were generally high and suggested compliance with guidelines for the prevention of cardiovascular events.
authors.affiliation: National Institute of Health Researcher, University of Colorado Health Sciences Center (UCHSC), Denver, USA.
authors.forename: Janice V
authors.initials: JV
authors.lastname: Huang
authors.forename: Adrianne W
authors.initials: AW
authors.lastname: Casebeer
authors.forename: Mary E
authors.initials: ME
authors.lastname: Plomondon
authors.forename: A Laurie W
authors.initials: AL
authors.lastname: Shroyer
authors.forename: Gerald O
authors.initials: GO
authors.lastname: McDonald
authors.forename: David
authors.initials: D
authors.lastname: Fullerton
authors.forename: Missy R
authors.initials: MR
authors.lastname: Bell
authors.forename: Janet
authors.initials: J
authors.lastname: Baltz
authors.forename: Frederick L
authors.initials: FL
authors.lastname: Grover
authors.forename: Francesca
authors.initials: F
authors.lastname: Cunningham
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D016208:Databases, Factual; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006787:Hospitals, Veterans; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000517:prevention & control* / Q000601:surgery; D010349:Patient Compliance / Q000706:statistics & numerical data*; D010607:Pharmacy Service, Hospital; D012307:Risk Factors; D014481:United States; D014493:United States Department of Veterans Affairs
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000924:Anticholesteremic Agents; D005343:Fibrinolytic Agents